Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Xiaofei Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5769-9308; OpenAlex author ID A5101677707. Sources: OpenAlex.

Their work

Papers
31 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 7 papers · 2019: 3 papers · 2020: 4 papers · 2021: 6 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 31

  1. Multifunctional Nanovaccine-Radiotherapy Synergy Drives Anti-Tumor Immunity via Multi-Cascade Cell Death for Pancreatic Cancer Therapy. Co-author DOI 10.1002/advs.77651↗
  2. ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1080/14796694.2025.2522061↗
  3. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Co-author DOI 10.1016/j.radonc.2023.109941↗
  4. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s13014-024-02493-8↗
  5. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… Co-author DOI 10.1016/j.eclinm.2022.101764↗
  6. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(22)00066-3↗
  7. Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer:… First author DOI 10.1136/bmjopen-2021-049382↗
  8. Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation th… First author DOI 10.21203/rs.3.rs-1919548/v1↗
  9. Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic ca… First author DOI 10.3389/fonc.2022.1021058↗
  10. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single… Co-author DOI 10.1016/j.radonc.2021.07.009↗
  11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(21)00286-2↗
  12. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(21)00529-5↗
  13. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. Co-author DOI 10.1111/cas.14486↗
  14. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Co-author DOI 10.3389/fonc.2021.688576↗
  15. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Cons… First author DOI 10.3389/fonc.2021.729490↗
  16. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. First author DOI 10.1016/j.jconrel.2020.06.001↗
  17. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. Co-author DOI 10.1177/1758835920977155↗
  18. Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. First author DOI 10.1186/s40644-020-00301-6↗
  19. Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of m… Co-author DOI 10.20892/j.issn.2095-3941.2019.0101↗
  20. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Tar… Co-author DOI 10.1016/j.ijrobp.2019.01.075↗
  21. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereo… Co-author DOI 10.1097/md.0000000000015064↗
  22. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: stu… First author DOI 10.1186/s13014-019-1254-8↗
  23. Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1553↗
  24. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD scor… Co-author DOI 10.1016/j.radonc.2018.08.012↗
  25. Combination of Pre-Treatment DWI-Signal Intensity and S-1 Treatment: A Predictor of Survival in Patients with Locally Advanced Pancreatic Cancer Receiving Ster… First author DOI 10.1016/j.tranon.2018.01.012↗
  26. Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting aut… First author DOI 10.1186/s13014-018-0956-7↗
  27. Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy. First author DOI 10.1186/s40644-018-0139-7↗
  28. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matc… Co-author DOI 10.2147/cmar.s163655↗
  29. Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pa… Co-author DOI 10.2147/cmar.s166713↗
  30. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Co-author DOI 10.1002/cam4.1164↗
  31. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally adva… Co-author DOI 10.1136/bmjopen-2016-013220↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huojun Zhang · 28 shared papers, 2016–2026 · strength 3.70
  2. Yangsen Cao · 24 shared papers, 2016–2025 · strength 3.29
  3. Lingong Jiang · 15 shared papers, 2019–2025 · strength 2.43
  4. Yusheng Ye · 12 shared papers, 2020–2025 · strength 2.06
  5. Wenyu Liu · 8 shared papers, 2018–2025 · strength 1.42
  6. Shuiwang Qing · 12 shared papers, 2016–2021 · strength 1.11
  7. Yuxin Shen · 10 shared papers, 2016–2021 · strength 0.88
  8. Gang Jin · 3 shared papers, 2019–2022 · strength 0.38
  9. Chengyi Huang · 1 shared paper, 2026 · strength 0.27
  10. Shengnan Ren · 2 shared papers, 2019–2020 · strength 0.24
  11. Changjing Zuo · 2 shared papers, 2019–2020 · strength 0.24
  12. Anyu Zhang · 2 shared papers, 2019–2020 · strength 0.24
  13. Ting‐Shi Su · 2 shared papers, 2020–2021 · strength 0.23
  14. Jianping Lu · 2 shared papers, 2018 · strength 0.18
  15. Xixu Zhu · 1 shared paper, 2021 · strength 0.12
  16. Di Chen · 1 shared paper, 2020 · strength 0.11
  17. Xiao Li · 1 shared paper, 2019 · strength 0.10
  18. Yuan Yuan · 1 shared paper, 2019 · strength 0.10
  19. Yu Zhang · 1 shared paper, 2018 · strength 0.10
  20. Suizhi Gao · 1 shared paper, 2019 · strength 0.09
  21. Yun Bian · 1 shared paper, 2019 · strength 0.09
  22. Kai Cao · 1 shared paper, 2019 · strength 0.09
  23. Shiwei Guo · 1 shared paper, 2019 · strength 0.09
  24. Hui Jiang · 1 shared paper, 2019 · strength 0.09
  25. Xiaohan Shi · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.